Although efforts are not yet at the contract stage at this early stage of development, they must be documented and agreed upon by the parties. In addition, the underlying values for measuring results, results themselves and all risk factors that may have a negative impact on the service provider`s efforts should also be agreed and clearly documented. The duration of the contract and the timing may vary depending on the target group and the actual results. Today, the effectiveness of multiple sclerosis treatment is generally evaluated within 18 to 24 months. However, most patients are enrolled in health plans each year; a results-based contract, which does not allow for breakpoints in a period of 6 to 12 months, may affect the value of payers if members` revenues occur. In the end, the payer must pay the entire drug at the time of delivery and cannot make a profit-based payment based on value until years later. This could be a budgeting challenge if efforts were made to estimate the potential performance of results-based contracts. Each party must invest in the process at an early stage. The client must have the appropriate resources for his internal analysis and the baseline of existing services. Both parties will need their project teams to invest time and effort in structuring deals and exclude external factors that may affect the measurable results that the service provider pays. Payers reported challenges in selecting criteria for outcome-based contracts in a progressive neurological disorder, such as multiple sclerosis. For example, because of their subjective definitions, relapses are considered an unpopular choice for an evaluation criterion. other candidates at the starting point, such as.B.
Changes in MRI over time, are not always directly correlated with the progression of multiple sclerosis disease,14, especially in the advanced stages of the disease.15 Despite the high cost of disease modification drugs for multiple sclerosis on the market, the number of these active substances and the variability of reactions in patients.15 Despite the high cost of disease modification drugs for multiple sclerosis on the market, the number of these active substances and the variability of reactions in patients multiple sclerosis is a mandatory therapeutic area for results-based adoption.